Which cat breeds is this suitable for?

It is suitable for small, extra small, toy, and giant breeds.

What is the lead time for production?

The average lead time is one month for both peak and off-season.

Wholesale Cat Food Glucosamine, Msm Hip & Joint Supplement for Cats Mobility Cat

Name: Wholesale Cat Food Glucosamine, Msm Hip & Joint Supplement for Cats Mobility Cat
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 2097302032

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$3.50

3,000 Pieces

Sample price:US$10.00/piece.Request sample

Product profile

Customization

Available

Type

Pet Nurture & Health Products

Application

Adult Pet

Appearance

Dry

Feature

Grain-Free

Spec

200g-499g

Flavour

Beef

Brand

Favor Baby

Transport Package

Bottle

Specification

100pieces/bottle

Trademark

favorbaby

Origin

China

Production Capacity

5000tons

Key features

Joint Health Support: Glucosamine, MSM, and chondroitin support cartilage and lubricate joints.

Grain-Free Formula: Safe for sensitive pets with a grain-free beef flavor profile.

Multi-Breed Suitability: Designed for small, extra small, toy, and giant breeds.

Comprehensive Certification: Manufactured under GMP, HACCP, ISO, and FDA standards.

Custom Branding Options: Private label services available for brand customization.

High Production Capacity: 500,000 pieces per year ensuring stable supply.

Flexible OEM/ODM Service: Professional OEM and ODM services with 20 R&D engineers.

Long Shelf Life: 2 years shelf life for extended product usability.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤11.01h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.